Plexium
Plexium is a clinical stage drug discovery and development company specializing in targeted protein degradation therapies, utilizing proprietary high-throughput cell-based screening technology to address high unmet medical needs.
Services
Plexium is a clinical stage drug discovery and development company focused on delivering targeted protein degradation therapies. Their primary service involves the rational design and discovery of monovalent protein degraders through a proprietary high-throughput cell-based screening (uHTS) technology. Plexium's platform is capable of discovering new molecular glues and direct degraders to target and degrade disease-related proteins in relevant cellular environments.
Technology
Plexium's platform is powered by a proprietary ultra-high-throughput (UHTS) cell-based screening technology. This platform combines screening purposefully designed 'on-bead' DNA encoded libraries in miniaturized cell-based assays, directly measuring the degradation of target proteins. The primary assay readout identifies compounds that degrade targets of interest in representative, disease-relevant cellular contexts. This innovative approach allows for the discovery of molecular glues and monovalent direct degraders that are difficult to target through traditional drug discovery methods.
Products
Plexium's product pipeline includes novel molecular glues and direct degraders aimed at difficult-to-drug targets, primarily for cancer treatment. One of their key products, PLX-4545, is a molecular glue that selectively degrades the IKZF2 transcription factor and has advanced into a Phase 1 clinical trial. Plexium is also working to advance potent degraders of therapeutically important proteins such as SMARCA2, CDK2, and cRAF, to address high unmet medical needs in various diseases.
Collaborations
Plexium has established significant collaborations to advance its drug discovery efforts. They have a neurodegenerative disease-focused collaboration with AbbVie and a multi-year, drug discovery collaboration with Amgen to identify novel targeted protein degradation therapies. These strategic partnerships aim to leverage Plexium's platform to accelerate the discovery and development of new treatments for challenging diseases.
Funding
In February 2022, Plexium announced a $102 million financing round. This funding is aimed at advancing the company's platform and expanding its pipeline of targeted protein degradation therapies. The financing supports the continued development of their innovative drug discovery technologies and the progression of their clinical trials.